Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426086 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
A Phase 2 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT02426086 is a Phase 2 study that has completed, run by Geron Corporation. The registered enrollment target is 107 participants.
The verdict
NCT02426086, a Phase 2 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus Kinase (JAK) inhibitor treatment. Key secondary endpoint includes overall survival.
Interventions
- DRUG Imetelstat 4.7 mg/kg
- DRUG Imetelstat 9.4 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02426086
The ClinicalTrials.gov registry entry for NCT02426086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imetelstat 4.7 mg/kg is the first listed.
NCT02426086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02426086 about?
NCT02426086 is a clinical study titled "Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor". The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus Kinase (JAK) inhibitor treatment. Key secondary endpoint includes overall su...
What is the current status of trial NCT02426086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2015-08-28. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT02426086?
The interventions under investigation include: Imetelstat 4.7 mg/kg (DRUG), Imetelstat 9.4 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02426086?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.